Get started
BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

BTAI chart


Full chart

BTAI upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.42 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−13.52 USD
Net income (FY)
‪−59.60 M‬ USD
Revenue (FY)
‪2.27 M‬ USD
Shares float
‪5.03 M‬
Beta (1Y)
1.16

Employees


Employees (FY)
37
Change (1Y)
−37 −50.00%
Revenue / Employee (1Y)
‪61.24 K‬ USD
Net income / Employee (1Y)
‪−1.61 M‬ USD

About BioXcel Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Vimal D. Mehta
Website
bioxceltherapeutics.com
Headquarters
New Haven
Founded
2017
FIGI
BBG00K20GVD2
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BTAI news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as BTAI.

Frequently Asked Questions


The current price of BTAI is 1.37 USD — it has decreased by −2.11% in the past 24 hours. Watch BioXcel Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioXcel Therapeutics, Inc. stocks are traded under the ticker BTAI.
BTAI stock has fallen by −2.80% compared to the previous week, the month change is a −20.11% fall, over the last year BioXcel Therapeutics, Inc. has showed a −95.65% decrease.
We've gathered analysts' opinions on BioXcel Therapeutics, Inc. future price: according to them, BTAI price has a max estimate of 1.00 USD and a min estimate of 1.00 USD. Watch BTAI chart and read a more detailed BioXcel Therapeutics, Inc. stock forecast: see what analysts think of BioXcel Therapeutics, Inc. and suggest that you do with its stocks.
BTAI reached its all-time high on Jul 20, 2020 with the price of 1,144.00 USD, and its all-time low was 1.29 USD and was reached on Apr 7, 2025. View more price dynamics on BTAI chart.
See other stocks reaching their highest and lowest prices.
BTAI stock is 6.72% volatile and has beta coefficient of 1.16. Track BioXcel Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is BioXcel Therapeutics, Inc. there?
Today BioXcel Therapeutics, Inc. has the market capitalization of ‪8.30 M‬, it has increased by 3.18% over the last week.
Yes, you can track BioXcel Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
BioXcel Therapeutics, Inc. is going to release the next earnings report on Aug 12, 2025. Keep track of upcoming events with our Earnings Calendar.
BTAI earnings for the last quarter are −1.50 USD per share, whereas the estimation was −2.72 USD resulting in a 44.85% surprise. The estimated earnings for the next quarter are −2.24 USD per share. See more details about BioXcel Therapeutics, Inc. earnings.
BioXcel Therapeutics, Inc. revenue for the last quarter amounts to ‪168.00 K‬ USD, despite the estimated figure of ‪300.00 K‬ USD. In the next quarter, revenue is expected to reach ‪400.00 K‬ USD.
BTAI net income for the last quarter is ‪−7.25 M‬ USD, while the quarter before that showed ‪−10.86 M‬ USD of net income which accounts for 33.20% change. Track more BioXcel Therapeutics, Inc. financial stats to get the full picture.
No, BTAI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 23, 2025, the company has 37 employees. See our rating of the largest employees — is BioXcel Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioXcel Therapeutics, Inc. EBITDA is ‪−49.12 M‬ USD, and current EBITDA margin is ‪−2.79 K‬%. See more stats in BioXcel Therapeutics, Inc. financial statements.
Like other stocks, BTAI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioXcel Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioXcel Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioXcel Therapeutics, Inc. stock shows the sell signal. See more of BioXcel Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.